[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Submission ::
Contact us::
Site Facilities::
Impact Factor
Impact Factor 2022: 1.9
5-Year Impact Factor: 2.2
Cite Score 2022: 3.9
SJR 2022: 0.447
SNIP 2022: 0.538

Publication Fee
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 5, Issue 2 (Int J Mol Cell Med 2016) ::
Int J Mol Cell Med 2016, 5(2): 114-122 Back to browse issues page
Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer
Atieh Zorrieh Zahra1 , Sepideh Kadkhoda1 , Behjati Farkhondeh1 , Fatemeh Aghakhani Moghaddam1 , Azadeh Badiei1 , Fereidoon Sirati2 , Hossein Afshin Alavi3 , Morteza Atri2 , Ramesh Omranipour2 , Elahe Keyhani 1
1- Genetics Research Center-University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2- Cancer Institute- Department of surgery- Tehran University of Medical Sciences, Tehran, Iran.
3- Pathology Ward-Day hospital,Tehran, Iran.
Abstract:   (9493 Views)

Male breast cancer is a rare disease with an increasing trend. Due to limited information especially about the genetic basis of the disease in Iran and the lower age of its onset, the disease requires more attention. The aim of this study was to screen the male patients with breast cancer for BRCA mutations as well as tissue markers of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER-2) and cytokeratin 5/6 (CK5/6). Ten Iranian males with breast cancer were selected regardless of their histologic subtypes, age and family history from patients referred to Mehrad, Day and Parsian hospitals in Tehran, Iran, during a two-year period. Paraffin blocks of the tumoral regions were tested for ER, PR, HER-2 and CK5/6 immunostaining. DNA extraction was carried out on the EDTA blood samples followed by Sanger sequencing. Immunohistochemistry results for ER, and PR were negative in 2 out of 10 patients, while the results of HER-2 and CK5/6 were negative in all the cases. A missense mutation in exon 18 of BRCA1 and a nonsense mutation in exon 25 of in BRCA2 were detected in one patient each. Both patients belonged to luminal A subtype. Despite the low number of patients in this study, it could be concluded that mutations in BRCA1 and BRCA2 occur in male breast cancer patients of luminal A subtype. The negative status of the tissue markers could not be used for the prediction of BRCA mutations.

Keywords: Male breast cancer, BRCA genes, human epidermal growth factor receptor, cytokeratin 5/6, estrogen receptor, progesterone receptor
Full-Text [PDF 425 kb]   (4318 Downloads)    
Type of Study: Original Article | Subject: Genetics & Disease
Received: 2015/10/29 | Accepted: 2016/01/31 | Published: 2016/05/9
Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zorrieh Zahra A, Kadkhoda S, Farkhondeh B, Aghakhani Moghaddam F, Badiei A, Sirati F, et al . Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer. Int J Mol Cell Med 2016; 5 (2) :114-122
URL: http://ijmcmed.org/article-1-407-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 5, Issue 2 (Int J Mol Cell Med 2016) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4652